Shionogi’s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA
Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA)...
BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment
Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA)...
Livzon Pharmaceutical Secures NMPA Approval for LZM012/XKH004, China’s First IL-17A/F Dual Inhibitor for Ankylosing Spondylitis
Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China’s National...
Changchun High & New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3Kα Inhibitor for PIK3CA-Mutant Solid Tumors
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...
Changchun High & New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received Investigational...
Legend Biotech Unveils First-in-Human Data for DLL3-Targeted CAR-T Therapy LB2102 in Relapsed Small Cell Lung Cancer at ASCO 2026
Legend Biotech Corporation (NASDAQ: LEGN) presented groundbreaking first-in-human (FIH) clinical data at the 2026 American...
Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American...
Novartis’ Scemblix Demonstrates Sustained Superiority Over Standard TKIs in Chronic Myeloid Leukemia with 144-Week ASC4FIRST Data
Novartis AG (NYSE: NVS) announced compelling long-term efficacy data from the pivotal ASC4FIRST Phase III...
Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) and Eli Lilly and Company (NYSE: LLY) announced...
BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma
Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the European Commission (EC) has granted marketing...
D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026
D3 Bio, a China-based biotechnology company, presented updated Phase I/II clinical data for elisrasib (D3S-001),...
Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026
Impact Therapeutics (HKG: 7630) presented updated Phase I/II clinical data for IMP1734 (EIK1003), a highly...
CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...
GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the...
LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026
LaNova Medicines Ltd., a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented Phase II clinical...
Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit
China’s National Medical Products Administration (NMPA) has granted approval for anbenitamab, a HER2 bispecific antibody...
Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design
Lynk Pharmaceuticals Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted clearance...
CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease
CF PharmTech Inc. (HKG: 2652) announced that China’s National Medical Products Administration (NMPA) has granted...
Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon
Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG...
Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market
Basecare Medical Device Co., Ltd. (HKG: 2170), a specialist in high-throughput sequencing-based assisted reproduction technologies,...